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Abstract: CONTEXT Diagnosis of subclinical adrenal hypercortisolism is based on several tests of the
hypothalamic-pituitary-adrenal axis to establish mild alterations of cortisol secretion and dysregulated
cortisol physiology. OBJECTIVE This study assessed whether plasma steroid profiles might assist diag-
nosis of subclinical Cushing’s syndrome (SC). DESIGN Retrospective cross-sectional study. SETTING
Two tertiary medical centers. PATIENTS Two hundred and eight patients were tested for hypercor-
tisolism among whom disease was excluded in 152 and confirmed in 21 with overt clinical Cushing’s
syndrome due to adrenal tumors (AC) compared to 35 with SC. Another 277 age- and gender-matched
hypertensive and normotensive volunteers were included for reference. MAIN OUTCOME MEASURES
Panel of 15 plasma steroids measured by mass spectrometry with classification by discriminant analysis.
RESULTS Patients with SC showed lower (P<0.05) plasma concentrations of dehydroepiandrosterone
and dehydroepiandrosterone-sulfate than subjects without SC. The largest increases (P<0.001) in plasma
steroids among patients with SC were observed for 11-deoxycortisol and 11-deoxycorticosterone. Never-
theless, concentrations of 11-deoxycorticosterone, 11-deoxycortisol and pregnenolone in patients with AC
were higher (P<0.05) than in those with SC. Patients with SC or AC could be distinguished from sub-
jects without disease using the above combination of steroids as precisely as with use of measurements of
serum cortisol after dexamethasone. The steroid combination provided superior diagnostic performance
compared to each of the other routine biochemical tests. CONCLUSIONS Distinct plasma steroid profiles
in patients with SC may provide a simple and reliable screening method for establishing the diagnosis.
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Context: Diagnosis of subclinical adrenal hypercortisolism i  based on several tests of the 
hypothalamic-pituitary-adrenal axis to establish mild alterations of cortisol secretion and 
dysregulated cortisol physiology.  
Objective: This study assessed whether plasma steroid profiles might assist diagnosis of 
subclinical Cushing’s syndrome (SC). 
Design: Retrospective cross-sectional study. 
Setting: Two tertiary medical centers. 
Patients:  Two hundred and eight patients were tested for hypercortisolism among whom 
disease was excluded in 152 and confirmed in 21 with overt clinical Cushing’s syndrome due 
to adrenal tumors (AC) compared to 35 with SC. Another 277 age- and gender-matched 
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Main Outcome Measures: Panel of 15 plasma steroids measured by mass spectrometry with 
classification by discriminant analysis. 
Results: Patients with SC showed lower (P<0.05) plasma concentrations of 
dehydroepiandrosterone and dehydroepiandrosterone-sulfate than subjects without SC. The 
largest increases (P<0.001) in plasma steroids among patients with SC were observed for 11-
deoxycortisol and 11-deoxycorticosterone. Nevertheless, concentrations of 11-
deoxycorticosterone, 11-deoxycortisol and pregnenolone in patients with AC were higher 
(P<0.05) than in those with SC. Patients with SC or AC could be distinguished from subjects 
without disease using the above combination of steroids as precisely as with use of 
measurements of serum cortisol after dexamethasone. The steroid combination provided 
superior diagnostic performance compared to each of t e other routine biochemical tests. 
Conclusions: Distinct plasma steroid profiles in patients with SC may provide a simple and 
reliable screening method for establishing the diagnosis. 
Our data suggest that the multistep biochemical testing for diagnosis of subclinical Cushing’s 
syndrome could be simplified by single plasma multisteroid measurements. . 
Introduction 
Up to 50% of patients with adrenocortical adenomas detected incidentally (adrenal 
incidentalomas) may have hypercortisolism [1].  In most such cases the classical clinical 
features of Cushing’s syndrome are absent. Such conditi s have been described as 
‘subclinical Cushing’s syndrome ’ [1], ‘subclinical utonomous glucocorticoid 
hypersecretion’ or subclinical hypercortisolism  [2]. In this article we use the term 
‘subclinical Cushing’s syndrome’ (SC) when referring to this entity. 
Dysregulated cortisol physiology with mild elevations of cortisol secretion is most often 
recognized during evaluation of adrenal incidentalomas to exclude hypercortisolism [2 3]. 
Insulin resistance, hypertension, obesity, dyslipidemia, impaired glucose tolerance and 
diabetes mellitus are frequently associated with bot  subclinical Cushing’s syndrome and 
overt Cushing’s syndrome, thereby contributing to cardiovascular complications and high 
mortality [4]. Vertebral fractures may also be features of otherwise asymptomatic cortisol 
excess in osteoporotic patients with SC [5].  
The aforementioned considerations and findings of a 45% prevalence of SC among 
patients with unilateral adrenal masses with size over 2.5 cm and CT-imaging attenuation 
below one Hounsfield unit indicate the potential importance of recognizing SC [2]. 
Nevertheless, a consistent consensus on the criteria used to diagnose SC has yet to be 
reached. Clinical, radiological and hormonal characteristics of this pathological condition all 
require consideration. Absence of clinical signs and symptoms related to cortisol 
hypersecretion in the presence of hypercortisolism provides the generally accepted criteria for 
SC but is weakened by reliance on recognition of clinical clues.  
Findings of a serum cortisol above 1.8 µg/dl after th  dexamethasone suppression test 
(DST) combined with adrenocorticotrophin (ACTH) cone trations below 10 pg/ml provide 
one of several criteria for establishing dysregulated cortisol secretion in SC [6]. Elevated 24-h 
urinary outputs of free cortisol (UFC) have been repo ted in some studies but are not reliable 
alone for diagnosis of either overt Cushing’s syndrome or SC [2 7]. Measurement of late-
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cortisol secretion in SC patients; however, with cut-off points of the late-night and midnight 
salivary cortisol ranging from 0.13 µg/dl to 0.55 µg/dl [8] use of this test alone is also 
unreliable for diagnosis of either AC or SC. Overall, diagnosis of SC remains difficult and 
requires a positive DST and at least another HPA axis aberration [9].  
Use of other adrenal steroids apart from cortisol for diagnosis of SC has not been widely 
investigated. Altered plasma concentrations of several steroids in patients with adrenocortical 
adenomas and SC, as measured by liquid chromatography-t ndem mass spectrometry (LC-
MS/MS), have suggested that steroid profiling may provide a useful tool for diagnosis of SC 
[10]. This has been further supported by an LC-MS/M steroid profiling study establishing a 
panel of steroids that can be used to identify patients with Cushing’s syndrome and 
discriminate those with and without ACTH-dependent subtypes [11]. Other studies have 
indicated that urinary steroid profiling may be usef l for diagnosis of overt clinical Cushing’s 
syndrome [12 13].  
Using panels of steroids for diagnosing disorders of adrenal steroidogenesis has a more 
than two decades history, particularly with gas chromatography-mass spectrometry methods 
applied to congenital adrenal hyperplasia and related disorders of sexual development [14 
15]. Use of steroid profiles in adrenal cortical disorders has more recently gained traction 
with methods employing LC-MS/MS that also take advantage of advances in computational 
mathematics. Through such advances there is potential for a paradigm shift from 
unidimensional to multidimensional diagnostic approaches utilizing basic multivariate 
discriminant and principal components analyses to more sophisticated machine learning 
methods [11 16 17].  
Based on the above promising leads and advances we u ed LC-MS/MS to analyze the 
plasma steroid profiles of patients with adrenocorti al adenomas associated with SC 
compared to profiles of patients in whom Cushing’s syndrome was excluded (EX) and 
patients with overt adrenal Cushing’s syndrome (AC).  The analysis took advantage of well 
characterized reference intervals in a series of 525 hypertensive and normotensive volunteers, 
all relevant data available by open access [19]. The aim was to establish from this panel a 
selection of steroids that could serve as a single test alternative to routine tests for 
discriminating patients with SC from AC and patients without disease.  
Methods 
Recruitment of Patients 
Patients were enrolled in this bi-centric cross-sectional study from outpatients referred to the 
Departments of Endocrinology at the Ludwig-Maximillians-Universität München and the 
University Hospital Dresden. Patients were tested for hypercortisolism due to findings of 
adrenal masses detected by computed tomography or magnetic resonance imaging as well as 
for investigation of secondary hypertension. No comparison was made between patients 
having bilateral adrenal masses with those having unilateral lesions. The test was also 
performed to screen for Cushing’s syndrome in overweight and obese subjects. Hormonal 
evaluations were also performed to rule out pheochromocytoma and primary 
hyperaldosteronism. The final study population was restricted to those with either 
confirmation or exclusion of disease according to current guidelines [18]. Patients with 
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Cortisol values (fasting serum cortisol >1.8 µg/dl) after an overnight dexamethasone 
suppression test (DST), 24h urinary free cortisol (upper cut-offs 75.4 µg/24h) (UFC), 
midnight salivary cortisol (SFC) (>1.5 ng/ml) as well as basal serum cortisol (upper cut-offs 
240 µg/l) and ACTH concentrations (<10 pg/ml) were performed to confirm presence of AC 
or SC. An abnormal dexamethasone suppression test (DST) as one initial screening test in 
combination with at least one other abnormal test of the hypothalamic-pituitary-adrenal axis 
was advocated for diagnosis of SC. Overt AC was thereby confirmed in 21 patients. Subjects 
with no relevant clinical features of Cushing’s syndrome were classified as SC (n=35) if they 
had biochemical evidence of hypercortisolism or as disease excluded (EX) if they showed no 
biochemical evidence of hypercortisolism (n=152).  
Reference population 
The reference control group was matched as closely as possible to combined patient groups 
according to age and sex. A total of 277 normotensive and hypertensive volunteers were 
thereby selected out of 525 subjects (all at Dresden) recruited initially for establishing 
specific reference intervals for each of the steroids f the plasma panel [19].  The reference 
population was included for comparisons to patients in whom hypercortisolism was excluded 
and to aid correction of impacts of differences in age and sex among the three different 
patient groups (Table 1). All subjects provided written informed consent under protocols 
approved by the local ethics committee at each center. 
Steroid profiling 
The 15 adrenal steroid panel including aldosterone, cortisol, 11-deoxycortisol, 21-
deoxycortisol, corticosterone, 11-deoxycorticosteron , aldosterone, 18-oxocortisol, 18-
hydroxycortisol, cortisone, progesterone, 17-hydroxyprogesterone, pregnenolone, 
androstenedione, dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) was 
assayed by LC-MS/MS as described elsewhere [20]. 
Cortisol after DST, UFC, SFC and basal plasma cortis l and ACTH were analyzed within 
the routine clinical laboratories at both centers. 
Blood sampling was performed in the morning between 08:00 to 10:00 A.M after an 
overnight fast. Samples were collected into blood tubes containing lithium heparin or 
ethylendiaminetetraacetic acid and stored at -80oC until analyses of steroid profiles. 
Statistical analyses 
Statistical analyses were carried out utilizing the JMP statistic software package (SAS 
Institute Inc., Cary, NC). The Wilcoxon and Steel Dwass all-pairs tests were used for non-
parametric comparisons of demographic and routine biochemical data involving multiple 
groups. For parametric multivariate analyses, all data were logarithmically transformed 
before analyses. Corrections for age and sex in comparisons that involved the reference 
population involved multivariate calculations of least square means using age and sex as 
covariates with final display of data derived by the exponents of logarithmically transformed 
data to calculate geometric means and respective plus and minus standard errors. For least 
square means multivariate comparisons, significance of differences were assessed using the 
Tukey HSD test. For other multivariate analyses (e.g., discriminant analyses) data were 
normalized according to age- and gender-specific upper cut-offs of reference intervals as 
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For distinguishing patients with and without SC, receiver-operating characteristic (ROC) 
curves were constructed by logistic regression. Selection of a minimal panel of the most 
useful steroids for diagnosis was established using stepwise regression. Discriminant analysis 
with stepwise variable selection was further employed to assess the use of plasma steroid 
combinations for distinguishing patients with SC from AC and EX groups. Details 
concerning the discriminant platform of the JMP stati ics software package are available on-
line (https://www.jmp.com/support/help/14-2/disciminant-analysis.shtml). Results from 
steroid profiling were compared to those derived from routine measurements of UFC, SFC, 
plasma ACTH and plasma cortisol before and after DST. Descriptions of underlying 
mathematical and statistical concepts, associated methodological details and additional 
statistical analyses are available in the on-line supplemental file [41]. 
Results 
Patient characteristics and routine test results 
Patients with SC were older at presentation compared to other groups while those with AC 
showed a higher proportion of females compared to other groups (Table 1). Plasma cortisol 
concentrations after DST in SC patients were as expected higher (P<0.05) than in the EX 
group but lower (P<0.005) compared to those of AC patients. Midnight salivary free cortisol 
as well as UFC revealed higher (P<0.05) values in AC und SC patients than in the EX group. 
Basal plasma ACTH concentrations were lower (P<0.01) in SC patients than in the EX group 
but higher (P<0.0005) compared to AC patients. Cortis l concentrations after DST showed 
minimal overlap between AC or SC patients and the EX group, in keeping with use of this 
test as part of the gold standard for classification. 
Steroid profiles 
Significances of differences among groups were assessed by models with multivariate 
analyses to correct for differences in sex and age (Table 2). Among the 15 steroids of the 
panel, 11-deoxycortisol and 11-deoxycorticosterone were consistently increased (P<0.05) in 
both groups of patients with AC and SC compared to both the reference and EX groups 
(Figure 1). Plasma concentrations of cortisol were increased (P<0.05) in AC and SC groups 
above the reference but not the EX group. Plasma aldosterone showed no differences between 
groups, whereas 18-oxocortisol and 18-hydroxycortisl in patients with SC and AC and the 
EX group were higher (P<0.05) than concentrations of the reference group.  
Plasma concentrations of DHEA and DHEA-S were the only two steroids that were 
consistently lower (P<0.05) in patients with AC and SC than both reference and EX groups, 
with additionally lower concentrations of both these two steroids in AC than SC (Figure 1). 
Androstenedione was lower in AC than the EX and reference groups. Corticosterone was 
higher (P<0.05) in SC compared to the EX group. There were no differences in plasma 
concentrations of 21-deoxycortisol, cortisone and 17-hydroxyprogesterone among the four 
groups, whereas pregnenolone showed unusually lower (P<0.05) concentrations in EX and 
SC groups compared to reference as well as SC compared to AC.  Progesterone 
concentrations were lower (P<0.05) in SC and AC groups compared to reference.  
Diagnostic test performance 
A combination of 14 steroids was established using a stepwise analysis to provide optimal 
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the analysis indicated 6 steroids (11-deoxycortisol; 11-deoxycorticosterone, DHEA-S, 
DHEA, androstenedione and progesterone) that provided the highest discriminatory power 
with respective F-ratios of 41.7, 35.6, 34.8, 28.6, 9 4 and 8.7. With omission of steroids to 
obtain different steroid combinations 11-deoxycortisol always maintained the highest rank. 
With discriminant analysis this combination provided a misclassification rate of only 14.4%. 
With exclusion of 18-oxo-cortisol, the combination f the remaining 14 steroids provided a 
lower misclassification rate of 4.8%. Using this combination, areas under ROC curves 
showed higher (P<0.01) diagnostic performance of the s eroid panel compared to salivary 
free cortisol, basal ACTH, basal serum cortisol, and UFC (Figure 2, Table 3). The area under 
the ROC curve for the steroid panel did not differ rom the area under the ROC curve for the 
DST. 
Classification of Patients with SC, AC and NS 
Routine measurements of UFC, midnight salivary freecortisol, basal plasma ACTH and 
serum cortisol combined with the DST provided optimal discrimination of the three groups of 
patients with areas under ROC curves of 1.000, 0.993  and 0.9941 for AC, EX and SC 
respectively (Figure 3). Eighty-three percent of all p tients with SC and 100% of patients 
with AC were correctly classified by the combination f all five routine measurements. Four 
percent of patients of the EX group were incorrectly lassified using the combination of 
routine tests. 
With use of the steroid panel 97% of patients with SC were correctly classified, whereas 
up to 5% of patients with AC and of the EX group were misclassified (Figure 3). Areas under 
the ROC curve of the steroid panel ranged from 0.9962, 0.9904 and 0.9901 for AC, EX and 
SC respectively, similar to those observed for the combination of routine tests (Figure 3). 
Although both methods could completely distinguish patients with SC from AC, 
identification of patients among the SC group suffered fewer false negatives with use of the 
steroid profile than with the routine test combination. 
Discussion 
The main findings of our study are two-fold. First, we show for the first time that the 
measurement of multiple steroids from a single baseline plasma sample is able to identify 
patients with SC with high accuracy and distinguish them from normal controls and subjects 
in who disease was excluded. Second, we demonstrate that patients with SC, although 
heterogeneous in terms of standard diagnostic tests and glucocorticoid output, have a distinct 
steroid fingerprint, which separates them from patients with AC in discriminant analysis. Our 
data extend those of our previous publications addressing similar diagnostic questions in 
primary aldosteronism [21-23]. All together these data suggest that in the future cumbersome 
multistep biochemical testing for diagnosis of adrenal pathologies could be radically 
simplified by single plasma multisteroid measurements. 
Numerous previous studies have shown that no single test to establish hypercortisolism 
has 100% sensitivity or perfect accuracy resulting in patients incorrectly labeled with SC due 
to false-positive results [24 25]. Lack of specificity of conventional tests can have far-
reaching consequences, as for example in patients with pronounced metabolic syndrome who 
might become candidates for unilateral adrenalectomy when presenting with false-positive 
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pressing problem.  Missing the correct diagnosis in a mildly symptomatic patient with a true 
cortisol hypersecreting tumor can delay adequate treatment with potential for an adverse 
outcome.   
Nocturnal salivary cortisol, an early hallmark of hypercortisolism, has been extensively 
shown in some studies to offer poor sensitivity for SC [1 9 22]. Our data confirm in a large 
data set a poor discrimination of patients with SC compared to those with AC using salivary 
free cortisol measurements. Elevations in UFC have been widely used to predict the chronic 
manifestation of subtle cortisol excess despite the drawbacks due to common sampling errors 
and problems with cross-reactivity to other steroids in immunoassays. Of note, patients with 
SC in our study had similar mean levels of UFC as patients without Cushing syndrome. 
However, UFC provided reasonable separation of AC patients from other groups. In 
summary, the ROC curves of the routine tests for diagnosis of SC in our study revealed lower 
diagnostic effectiveness of these methods compared to the selected steroid combination.  
Interestingly, of the various tests examined for differentiating patients with and without 
SC all performed poorly except for the DST. This can be in part explained by the strong 
emphasis clinicians involved in our study likely placed on the DST, which according to the 
recently published European guideline [14] classifie  autonomous cortisol secretion 
according to this test. There has been disagreement on the best cut-off for cortisol after DST. 
A recent study revealed that the optimal value could even be lower than the commonly used 
value of 1.8 µg/dl (50 nmol/l) [2 26]. The response of cortisol after DST in patients who do 
not exhibit signs and symptoms specific for AC have to be analyzed together with other 
results from routine tests. Indeed, some of the patients with positive results of the DST were 
eventually categorized as NS since there was no evidence of abnormal cortisol excess in other 
hormonal parameters, making this a source of uncertainty [24]. The more common threshold 
value of 1.8 µg/dl was used in our study to show that e level of cortisol after the DST 
remains the most sensitive assay alongside the combination of steroids to subgroup patients 
with subtle autonomous cortisol hypersecretion. 
More recently, the discussion about cut-offs for correct classification of hormonal excess 
has moved towards prediction of long-term outcomes in SC. It is a well-established concept 
that hypercortisolism can lead to associated comorbidities, such as metabolic, 
musculoskeletal and cardiovascular diseases [2], similar to patients with overt Cushing's 
syndrome. A retrospective study analysed outcome, using the classification of patients with 
adrenal incidentalomas as non-secreting or as stable SC according to the cortisol levels after 
DST and in another cohort with increasing cortisol levels on follow-up. This arbitrary 
classification was able to identify patients with increased cardiovascular events and mortality 
rates [27].The data were confirmed by two quite similar studies [28 29]. Future studies will 
need to show whether a classification based on steroid finger printing will make it possible to 
predict long term outcome in patients with SH. 
A number of studies have reiterated the advantages of LC-MS/MS over immunoassays 
for measurements of steroids [10 11 15]. Here we additionally show that plasma 11-
deoxycortisol, 11-deoxycorticosterone, DHEA, DHEA-S and corticosterone can reliably 
distinguish patients with and without SC. Circulating levels of DHEA-S have been found in 
the high normal range in patients with ACTH-dependent CS, whereas both AC and SC are 
characterized by decreased circulating basal concentrations of DHEA-S and DHEA [30-32]. 
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to be exclusively associated with adrenocortical adenoma [33] [11]. Indeed our data also 
confirm lowered DHEA and DHEA-S in patients with AC and SC, supporting previous 
suggestions that ACTH is a major determinant of their s cretion [34 35]. 
Low levels of progesterone in both SC and AC patients in our study can be explained by 
two mechanisms. Continuously elevated cortisol levels inhibit the pituitary-gonadal axis 
leading to anovulatory cycles, prohibiting the action of progesterone in the uterus as well as 
the secretion of GnRH from the thalamus [36]. This effect likely contributes to low 
progesterone in our mainly female premenopausal cohort with florid AC. In the gender-
balanced, predominantly postmenopausal SC cohort, precursor substrate flow characteristics, 
enhanced by partially suppressed plasma ACTH, could result in the pattern of low plasma 
pregnenolone and progesterone concentrations. Indeed, chronic ACTH excess has been 
shown to influence intraadrenal utilization of delta5-pregnene leading to elevation of 
pregnenolone [37 38], which is very much in line with our findings.  
Our study has several limitations, one of which involved the higher age of the SC than 
other cohorts and the female predominance of the AC cohort. Since the latter is an established 
observation in AC [39] and since adrenal incidentalomas that prompt consideration of 
hypercortisolism are predominantly found in the elderly [2 40], neither of these issues are 
easily addressed by matched populations. Rather we addressed these potential confounders by 
use of models and normalizations that took advantage of data from a larger reference 
population. It nevertheless remains possible that even with these corrections age, sex and 
menstrual phase differences may have contributed to differing patterns of steroids among AC 
and SC groups. Another limitation was that the diagnosis and exclusion of hypercortisolism 
was based on routine tests that are not infallible. Indeed findings that some steroids showed 
differences between reference and EX groups and that the EX group showed levels of many 
steroids intermediate between reference and SC and AC groups raises the possibility of 
milder forms of adrenal cortical dysfunction within the EX group that were not identified by 
routine tests.  Finally, it would have been useful to assess outcomes after adrenalectomy. 
However, the indication of adrenalectomy for patients with SC is often not achieved. 
In conclusion, this study establishes a method to ientify patients with SC using LC-
MS/MS measurements of a panel of adrenal steroids. Performance of the steroid profile was 
more advanced than salivary and urinary free cortisol and showed similar accuracy to use of 
routine test combinations that included the DST. Thus, the plasma steroid panel could serve 
as a single test alternative to screen for SC or toconfirm the findings on DST. Versatility of a 
single steroid profiling method for detecting other disorders of adrenal steroidogenesis 
provides another advantage for use of the method in the routine laboratory.  
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Figure 1. Results of steroids of the 15-steroid panel in patients with ACTH-independent 
Cushing’s syndrome (AC and SH) and in patients in whom the disease was excluded 
compared to that of the reference population. Values of all steroids are shown as least square 
means corrected for age and sex and determined from exponents of logarithmically-
transformed data (i.e geometric means) with similarly determined positive and negative 
standard errors. All figures depict plasma steroid c ncentration in ng/mL. *P<0.05, different 
from reference; †P<0.05 different from excluded; §P<0.05, different from adrenal Cushing. 
Figure 2. Results of model comparisons of the steroid profile and routine diagnostic test. 
ROC curves are shown altogether in one panel for the 5 routine screening tests and a 
selection of 14 steroids of the steroid panel, which exhibit optimal discrimination of patients 
with ACTH-independent Cushing’s syndrome to patients i  whom the disease was excluded. 
Prediction accuracy of each group was measured as are  under the curve (AUC) in related 
table. The groups are distinguished by different color lines. 
Figure 3. Results of discriminant analyses for use of routine diagnostic tests (A,B,C) 
compared to 14 steroids of the steroid panel (D,E,F) that provided optimal discrimination of 
the 3 patient groups (adrenal Cushing      , subclinical hypercortisolism      , excluded      ). 
Two-dimensional canonical plots are shown in panels B and E; ROC curves with areas under 
curves are shown in panels A and D; whereas predicted versus actual groupings according to 
discriminant analyses are shown in panels C and F. Routine diagnostic tests included 
measurements of salivary and urinary free cortisol, DST and basal plasma cortisol, and basal 
plasma ACTH. Steroids for the selected steroid profile included 11-deoxycortisol, 11-
deoxycorticosterone, DHEA, DHEA-S, androstenedione, aldosterone, cortisol, 
corticosterone, cortisone, 18-hydroxycortisol, 21-deoxycortisol, 17-hydroxyprogesterone, 
progesterone and pregnenolone. For the analyses of routine clinical tests, complete results for 
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Table 1. Characteristic of data and routine biochemical test r ults for patients screened for  













Reference 277 99/178 47 (19-81)      
Excluded 152 58/94 48 (16-80) 1.1 (0.5-4.8) 1.1 (0.1-14.9) 84 (47-286) 62 (4-191) 17 (1-244) 
Subclinical 
Cushing 35 17/18 65* § (45-80)
3.6 *§ (1.8-
20.6) 2.4* (0.2-9) 74§* (4.7-257) 63§ (5-145) 12§* (1-40) 
Adrenal 
Cushing 21 3/18 46 (17-72) 14* (2.7-23.9) 3.9* (0.3-11.8) 156* (21-271) 599* (82-195) 4* (2-35) 
ᶲ Data for age and routine biochemistry are shown as median and ranges. ACTH, adrenocorticotropin. DX, 
dexamethasone ; * p<0.05, different from excluded; § p<0.05, different from adrenal Cushing; ¶ p<0.05, 
different from reference 
Table 2. Effect of age and gender in Plasma concentration of adrenal steroids in all groups of 
population 
Steroid Model Effect p-value 
 Grouping Age Gender 
11-Deoxycortisol <.0001* 0.7802 <.0001* 
11-Deoxycorticosterone <.0001* 0.2416 0.8601 
DHEA <.0001* <.0001* 0.1527 
DHEA-SO4 <.0001* <.0001* <.0001* 
Aldosterone 0.2236 0.0058* 0.7109 
Androstenedione 0.0012* <.0001* 0.0098* 
18-Hydroxycortisol <.0001* 0.1432 <.0001* 
Pregnenolone <.0001* <.0001* 0.1417 
Cortisol 0.0001* <.0001* 0.9772 
18-oxocortisol <.0001* 0.0206* 0.0037* 
Cortisone 0.1724 <.0001* 0.0044* 
21-Deoxycortisol 0.2211 0.4671 0.0152 
Corticosterone 0.0147* <.0001* 0.5445 
Progesterone 0.0178* <.0001* <.0001* 
17-Hydroxyprogesterone 0.4040 <.0001* <.0001* 
*Significantly involved effect 
Table 3. Probability models of steroid profile compared to all five routine diagnostic tests 
Probability (Subclinical Cushing) Predictor 
Vs. Probability (Subclinical Cushing) 
Predictor Probability >Chi2 
Steroid Profile DST Serum Cortisol 0.4053 
Steroid Profile Saliva Free Cortisol <.0001* 
Steroid Profile Basal Plasma Cortisol <.0001* 
Steroid Profile Basal Plasma ACTH <.0001* 
Steroid Profile Urinary Free Cortisol <.0001* 
DST Serum Cortisol Saliva Free Cortisol <.0001* 
DST Serum Cortisol Basal Plasma Cortisol <.0001* 
DST Serum Cortisol Basal Plasma ACTH <.0001* 
DST Serum Cortisol Urinary Free Cortisol <.0001* 
Saliva Free Cortisol Basal Plasma Cortisol 0.3550 
Saliva Free Cortisol Basal Plasma ACTH 0.0344* 
Saliva Free Cortisol Urinary Free Cortisol 0.6491 
Basal Plasma Cortisol Basal Plasma ACTH 0.1534 
Basal Plasma Cortisol Urinary Free Cortisol 0.6828 
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Adrenal Cushing 20 0 1 95% 
Subclinical Cushing 0 34 1 97% 

































































Adrenal Cushing 13 0 0 100% 
Subclinical Cushing 0 24 5 83% 
Excluded 2 3 122 96% 
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